Larimar Therapeutics (LRMR) Stock Price, News & Analysis

Company Overview

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania.

Key Stats

• Today's Range: $4.00 to $4.08
• 50-Day Range: $3.05 to $4.37
• 52-Week Range: $2.71 to $6.42
• Volume: 52,798 shs
• Average Volume: 2.69 million shs
• Market Capitalization: $418.64 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $11.67
• Consensus Rating: Buy

Larimar Therapeutics Stock Analysis - MarketRank™

Larimar Therapeutics scored higher than 73% of companies evaluated by MarketBeat, and ranked 208th out of 920 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.6 / 5
• Analyst Rating: Buy

Consensus Rating

Larimar Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.10, and is based on 3 strong buy ratings, 6 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Larimar Therapeutics has a consensus price target of $11.67, representing about 188.1% upside from its current price of $4.05.

Amount of Analyst Coverage

Larimar Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Larimar Therapeutics are expected to grow in the coming year, from ($1.50) to ($1.32) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Larimar Therapeutics is -2.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Larimar Therapeutics is -2.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Larimar Therapeutics has a P/B Ratio of 3.29. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

13.48% of the float of Larimar Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Larimar Therapeutics has a short interest ratio ("days to cover") of 11.23, which indicates bearish sentiment.

Change versus previous month

Short interest in Larimar Therapeutics has recently increased by 10.28%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Larimar Therapeutics does not currently pay a dividend.

Dividend Growth

Larimar Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 3.2 / 5
• News Sentiment: 1.14

News Sentiment

Larimar Therapeutics has a news sentiment score of 1.14. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.90 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Larimar Therapeutics this week, compared to 3 articles on an average week.

Search Interest

Only 11 people have searched for LRMR on MarketBeat in the last 30 days. This is a decrease of -59% compared to the previous 30 days.

MarketBeat Follows

10 people have added Larimar Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 67% compared to the previous 30 days.

Company Ownership

• Score: 3.7 / 5
• Insider Trading: Acquiring Shares

Net Insider Buying

Over the last three months, insiders have purchased a net $167,000.00 in company stock, which represents 0.0397% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, Larimar Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $167,000.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

4.00% of the stock of Larimar Therapeutics is held by insiders.

Percentage Held by Institutions

91.92% of the stock of Larimar Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/04/2026
• Today: 8/28/2026
• Next Earnings (Estimated): 11/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:LRMR
• CIK: 1374690
• Web: larimartx.com
• Phone: (844) 511-9056
• Fax: N/A
• Employees: 30
• Year Founded: 2005

Price Target and Rating

• Average Price Target for Larimar Therapeutics: $11.67
• High Price Target: $21.00
• Low Price Target: $5.00
• Potential Upside/Downside: +189.5%
• Consensus Rating: Buy
• Rating Score (0-4): 3.10
• Research Coverage: 10 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.95)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$165.67 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -137.39%
• Return on Assets: -97.65%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.70
• Quick Ratio: 4.70

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.23 per share
• Price / Book: 3.28

Miscellaneous

• Outstanding Shares: 103,880,000
• Free Float: 99,728,000
• Market Cap: $418.64 million
• Optionable: Optionable
• Beta: 0.81